Joseph A Scarola

Suggest Changes
Learn More
BACKGROUND The efficacy and safety of sirolimus (SRL) plus tacrolimus (TAC) versus SRL plus cyclosporine (CsA) were compared in high-risk renal allograft recipients. METHODS Evaluable patients(More)